Literature DB >> 34999791

Late surgical conversion of failed Multilayer Flow Modulator stenting in thoraco-abdominal aneurysms.

Simone Salvati1, Victor Bilman1, Andrea Melloni1, Domenico Baccellieri1, Andrea Kahlberg1, Germano Melissano1, Roberto Chiesa1, Luca Bertoglio1.   

Abstract

OBJECTIVES: The aim of this study was to report the outcomes of open or hybrid repair of failed thoraco-abdominal aortic aneurysm endovascular treatment with Multilayer Flow Modulator (MFM) stents.
METHODS: All patients who underwent open or hybrid repair of a failed MFM aortic treatment were retrospectively analysed. Perioperative and postoperative data, as well as midterm survival, were assessed.
RESULTS: Between 2013 and 2020, 39 patients received an open or hybrid conversion after endovascular treatment. Five of them [13%; 4 males; median age 68 years (interquartile range 66-76)] were previously treated with aortic MFM stents (Cardiatis, Isnes, Belgium). Among these, the median interval between index repair and conversion was 84 months (interquartile range 75-84). The median aneurysm diameter was 9.6 cm (interquartile range 8-10). Renovisceral vessels steno-occlusion was highly prevalent: 2 renal arteries were occluded; 3 coeliac trunks, 2 renal arteries and 1 superior mesenteric artery had a >70% ostial stenosis. Open standard thoraco-abdominal aneurysm conversion was performed in 3 fit patients, while a hybrid approach with visceral debranching and tube endografting was performed in 2 high-risk patients. Two patients (2 open repairs) died intraoperatively, and 1 (hybrid repair) postoperatively. The 2 successfully treated patients are alive at 4- and 34-month follow-up, respectively, with patent visceral branches.
CONCLUSIONS: Open or hybrid thoraco-abdominal aortic aneurysm treatment after failed endovascular aortic repair with MFM stents might be the only surgical option to address sac enlargements and ruptures or branch-related failures. However, both procedures had a poor prognosis due to both the impaired preoperative patient's status and the surgical complexity in the presented series.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Endovascular aneurysm repair; Endovascular failure; Multilayer Flow Modulator; Open conversion; Thoraco-abdominal aortic aneurysm

Mesh:

Year:  2022        PMID: 34999791      PMCID: PMC8923416          DOI: 10.1093/icvts/ivab224

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  26 in total

Review 1.  Reporting standards for endovascular aortic aneurysm repair.

Authors:  Elliot L Chaikof; Jan D Blankensteijn; Peter L Harris; Geoffrey H White; Christopher K Zarins; Victor M Bernhard; Jon S Matsumura; James May; Frank J Veith; Mark F Fillinger; Robert B Rutherford; K Craig Kent
Journal:  J Vasc Surg       Date:  2002-05       Impact factor: 4.268

2.  Predicting the Need for Intra-operative Large Volume Blood Transfusions During Thoraco-abdominal Aortic Aneurysm Repair.

Authors:  M Pieri; P Nardelli; M De Luca; G Landoni; S Frassoni; G Melissano; A Zangrillo; R Chiesa; F Monaco
Journal:  Eur J Vasc Endovasc Surg       Date:  2017-01-06       Impact factor: 7.069

3.  Hybrid procedures for thoracoabdominal aneurysms.

Authors:  Germano Melissano; Roberto Chiesa
Journal:  J Endovasc Ther       Date:  2009-08       Impact factor: 3.487

4.  Editor's Choice - Management of Descending Thoracic Aorta Diseases: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS).

Authors:  V Riambau; D Böckler; J Brunkwall; P Cao; R Chiesa; G Coppi; M Czerny; G Fraedrich; S Haulon; M J Jacobs; M L Lachat; F L Moll; C Setacci; P R Taylor; M Thompson; S Trimarchi; H J Verhagen; E L Verhoeven; P Kolh; G J de Borst; N Chakfé; E S Debus; R J Hinchliffe; S Kakkos; I Koncar; J S Lindholt; M Vega de Ceniga; F Vermassen; F Verzini; P Kolh; J H Black; R Busund; M Björck; M Dake; F Dick; H Eggebrecht; A Evangelista; M Grabenwöger; R Milner; A R Naylor; J-B Ricco; H Rousseau; J Schmidli
Journal:  Eur J Vasc Endovasc Surg       Date:  2017-01       Impact factor: 7.069

5.  One-year outcomes following repair of thoracoabdominal aneurysms with the multilayer flow modulator: report from the STRATO trial.

Authors:  Claude D Vaislic; Jean Noël Fabiani; Sidney Chocron; Jacques Robin; Victor S Costache; Jean-Pierre Villemot; Jean Marc Alsac; Pascal N Leprince; Thierry Unterseeh; Eric Portocarrero; Yves Glock; Hervé Rousseau
Journal:  J Endovasc Ther       Date:  2014-02       Impact factor: 3.487

Review 6.  Systematic Review and Patient-Level Meta-analysis of the Streamliner Multilayer Flow Modulator in the Management of Complex Thoracoabdominal Aortic Pathology.

Authors:  Niamh Hynes; Sherif Sultan; Ala Elhelali; Edward B Diethrich; Edel P Kavanagh; Mohamed Sultan; Florian Stefanov; Patrick Delassus; Liam Morris
Journal:  J Endovasc Ther       Date:  2016-03-17       Impact factor: 3.487

Review 7.  Conventional markers of kidney function.

Authors:  Sean M Bagshaw; R T Noel Gibney
Journal:  Crit Care Med       Date:  2008-04       Impact factor: 7.598

8.  One-year results of the multilayer flow modulator stent in the management of thoracoabdominal aortic aneurysms and type B dissections.

Authors:  Sherif Sultan; Niamh Hynes
Journal:  J Endovasc Ther       Date:  2013-06       Impact factor: 3.487

9.  Early and midterm outcome of Multilayer Flow Modulator stent for complex aortic aneurysm treatment in Germany.

Authors:  Walid Ibrahim; Konstantinos Spanos; Andreas Gussmann; Christoph A Nienaber; Joerg Tessarek; Heinrich Walter; Jörg Thalwitzer; Sebastian E Debus; Nikolaos Tsilimparis; Tilo Kölbel
Journal:  J Vasc Surg       Date:  2018-03-27       Impact factor: 4.268

10.  Comparison of renal perfusion solutions during thoracoabdominal aortic aneurysm repair.

Authors:  Yamume Tshomba; Andrea Kahlberg; Germano Melissano; Giovanni Coppi; Enrico Marone; Denise Ferrari; Rosalba Lembo; Roberto Chiesa
Journal:  J Vasc Surg       Date:  2013-12-28       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.